Effective collaboration between hematologists and cardiologists facilitated successful control of reversible dasatinib-related pulmonary arterial hypertension and treatment-free remission of chronic myeloid leukemia: a case report.

The BCR-ABL1 tyrosine kinase inhibitor dasatinib is effective in chronic myeloid leukemia (CML) treatment. The major known adverse effects of dasatinib include pleural effusion and pulmonary arterial hypertension (PAH); however, the underlying mechanisms remain unclear. This case report describes a two-step dasatinib dose reduction decided by multi-disciplinary collaboration between cardiologists and hematologists for the management of PAH that led to treatment-free remission (TFR), suggesting an important improvement in the field. Herein, a 43-year-old woman with CML was administered 100 mg of dasatinib daily as a first-line therapy from May 2014. There were no evident abnormalities on her electrocardiogram and transthoracic echocardiography (TTE) charts before she started taking dasatinib. She developed leg edema in June 2015, and the TTE showed a high transtricuspid pressure gradient value. Based on these findings, we diagnosed PAH and right-sided heart failure due to dasatinib. However, since it was confirmed that the molecular response (MR

Informations de copyright

© The Author(s) under exclusive licence to The Japan Society of Clinical Oncology 2022.

Déclaration de conflit d'intérêts

Conflict of interestsZhensheng Hua has no conflicts of interest. Takuya Oyakawa has no conflicts of interest. Aya Ebihara has no conflicts of interest. Yasuhito Terui received personal fees (from Janssen, AbbVie, Celgene, ONO, Eisai, Takeda, MSD, and CHUGAI), research funding from Bristol-Myers Squibb, and Scholar donations (from Ono, Esai and Takeda). Taro Shiga received personal fees from Bristol-Myers Squibb, Daiichi-Sankyo and Bayer.